Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens

J Clin Pharmacol. 2016 Apr;56(4):492-6. doi: 10.1002/jcph.612. Epub 2015 Oct 20.
No abstract available

Keywords: HIV/AIDS; central nervous system; clinical pharmacology.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / cerebrospinal fluid*
  • Anti-HIV Agents / therapeutic use
  • Blood-Brain Barrier / metabolism
  • Cerebrospinal Fluid / metabolism*
  • Cerebrospinal Fluid / virology
  • Emtricitabine / cerebrospinal fluid*
  • Emtricitabine / therapeutic use
  • Female
  • HIV Protease / metabolism*
  • HIV Protease Inhibitors / cerebrospinal fluid
  • HIV Protease Inhibitors / therapeutic use*
  • HIV-1 / drug effects*
  • HIV-1 / metabolism
  • Humans
  • Male
  • Middle Aged
  • Prodrugs / therapeutic use
  • RNA, Viral / cerebrospinal fluid
  • Tenofovir / cerebrospinal fluid*
  • Tenofovir / therapeutic use

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • Prodrugs
  • RNA, Viral
  • Tenofovir
  • HIV Protease
  • p16 protease, Human immunodeficiency virus 1
  • Emtricitabine